source
- Neumora Therapeutics halts lead depression drug after two more Phase 3 failures, plans 35% staff cutsNeumora Therapeutics announced that its lead depression candidate will be discontinued after it did not meet primary endpoints in two additional Phase 3 trials. The company said the data were consi…
- HMNC Brain Health raises $50M Series B to advance two depression drugsHMNC Brain Health announced it has closed a $50 million Series B financing round. The capital will be used to move two depression drug candidates into mid-stage clinical trials. The round was led…